We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Netscientific Plc | LSE:NSCI | London | Ordinary Share | GB00BN4R5Q82 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.50 | -0.79% | 62.50 | 60.00 | 65.00 | 63.00 | 62.50 | 63.00 | 29,011 | 15:03:36 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 1M | -3.09M | -0.1312 | -4.76 | 14.73M |
Date | Subject | Author | Discuss |
---|---|---|---|
02/4/2017 23:51 | Good update on Vortex. Results in the morning - they will have to demonstrate that they can get to profitability without having to tap for cash. It will be interesting to see how they spin things. Free float is tiny and this gives rise to significant swings on any slight volume. If there is any good news, it will be impossible to buy a reasonable line without it being driven higher - the 5% move late Friday was on negligible volume.. Naturally, that works both ways. | yasx | |
29/3/2017 10:32 | No - invest and let the story unfold. Commercialisation of nascent projects is not some swift overnight process | yasx | |
29/3/2017 09:13 | hold and hope then eh yasx? | runwaypaul | |
14/3/2017 19:48 | Or, alternatively, the various assets within the portfolio group receive external funding to take them to the point of commercialisation. Be it noted that some of these are now at the stage of commercialisation so sooner or later revenues will start appearing, though I accept the cost base is too high and should be reduced. | yasx | |
14/3/2017 12:35 | £1 million a month you say......piggies having a good feed then.....what happens in a few months when its nearly all gobbled up? likely pawing over the confetti machine instruction handbook as we post. | loveandmoney1 | |
12/3/2017 19:21 | Loveandmoney, Plucking figures out of thin air is a strategy for novice punters. Any reference to facts to support your view? No, thought not. Given last reported cash (some 8 months ago) indicated cash balance of £15.8 mln, I do not see how you come up with that assessment. Even allowing for £1mln spend per month, there is still a healthy cash pile and all of the businesses have received collective funding from external sources in excess of £15mln. This is one for the long term, and the £5 target is intact. This is dwindling on small volumes because it is thinly traded - I see no sign of a significant holder selling, and the free float is tiny thus moves seem exaggerated. | yasx | |
12/3/2017 08:30 | 15m cap looks about right here. | loveandmoney1 | |
10/3/2017 12:11 | selling at 50 now..... | runwaypaul | |
08/3/2017 01:20 | I retain my holding - a nascent play in this sector is an investment not a trade. Those who are worried cann sell out. I am not. As for TRIN, well, you are following Zengas. Why don't you ask him who alerted him to the likely tremendous value at 2p, and, I for one remained in until yesterday at over 18p, all laid out every step of the way. You only arrived at TRIN since you follow me around. | yasx | |
07/3/2017 15:23 | There is nothing to say here, no reports, no management meetings, its all disappointing to followers.Meanwhile, TRIN up 25% since I flagged it here and more to come - Research Zengas and Big Fella posts on that bb. Do some research and think for yourselves, investors here are trapped in an illiquid stock that slowly falls as cash disappearsI stand by a fund raising or diluting deal this year. | che7win | |
07/3/2017 15:05 | ...and flush. | runwaypaul | |
07/3/2017 08:28 | Yasmin - all you have done here is shown yourself to be no better than the ramping halfwits you see on other threads.Good luck with this "investment". Looks more likely to see 30p than a quid. | beeks of arabia | |
07/3/2017 08:14 | selling @55p now.... | runwaypaul | |
28/2/2017 13:00 | Heading to 40p sometime imo. | blueball | |
28/2/2017 09:56 | Escape, I thought the bottom had been called here: "yasX 16 Feb '17 - 01:37 - 632 of 641 1 0 Meanwhile NSCI holding firm the past few days - looks like Chewin was advising selling yet another stock at the very bottom. He really is a perfect contrarian signal." Anyone investing here must be looking years out, the money is dead right now, who would buy a chart like that until there is a turnaround - go where the money is (e.g the market is keen on TRIN ). | che7win | |
27/2/2017 21:57 | An unacceptable share price performance. Come on Netscientific , lets do the jiggle jiggle! | escapetohome | |
27/2/2017 14:22 | Where have all the buyers gone. | blueball | |
22/2/2017 14:53 | Yep, that's the long and short of your contributions. Yas - It would be good to get some further guidance on this one. When do you think this will add to the bottom line and are they more likely to sell before that point? | beeks of arabia | |
22/2/2017 14:46 | zzzzzzzzzzzzzzzzzzzz | runwaypaul | |
22/2/2017 10:40 | Needs volume. | beeks of arabia | |
22/2/2017 08:58 | 22 February 2017 NetScientific plc ("NetScientific" or the "Company" or the "Group") Vortex Biosciences Announces Commercial Launch of Fully Automated Liquid Biopsy System for CTC Isolation London, UK - 22 February 2017 - NetScientific plc (AIM:NSCI), the transatlantic healthcare IP commercialisation Group, announces that its portfolio company, Vortex Biosciences, has begun the commercial launch of the VTX1 Liquid Biopsy System; its fully automated benchtop system for collecting intact circulating tumour cells (CTCs) that are shed by tumours, using patented innovative microfluidic technology. NetScientific shareholding in Vortex is 95% and as of 31 December 2016, the Group has invested GBP13.1 million. Grant funding received to develop the underlying technology, prior to Vortex's formation, was GBP1.6 million. Commenting on the news, François R. Martelet, Chief Executive Officer of NetScientific, said: "We are pleased to announce the commercial launch of Vortex's VTX-1 Liquid Biopsy System into research labs. We believe the technology has several key advantages over current approaches to CTC isolation and has the potential to make a meaningful impact on cancer research and assist the development of innovative diagnostics and therapeutics. The commercial launch is a critical milestone for Vortex and brings our portfolio company closer to significant value creation." | escapetohome | |
22/2/2017 08:06 | Great news! | yasx | |
16/2/2017 12:29 | However i bet my dad can fight your dad!Pathetic. Give it a rest you two. | beeks of arabia | |
16/2/2017 12:28 | Oh really? No doubt you know, as I posted nearly all my trades from August last year to December as they happened on advfn - they are there for all to see - posted upfront - so you can see where and how I made profits. I'm contrarian, unlike you who follows Zengas, I call it out the way I see it. I'm honest enough to say when I make mistakes, you of course never make mistakes. BTW, I don't recall ever calling this out as a sell as I'm not qualified to give financial advice - if I did however, it might have saved horrendous losses for some. | che7win |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions